Cingulate Inc (CING)
4.12
-0.10
(-2.37%)
USD |
NASDAQ |
Nov 15, 13:54
Cingulate Research and Development Expense (Quarterly): 1.428M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.428M |
| June 30, 2024 | 1.881M |
| March 31, 2024 | 1.807M |
| December 31, 2023 | 4.985M |
| September 30, 2023 | 3.924M |
| June 30, 2023 | 4.456M |
| March 31, 2023 | 2.129M |
| December 31, 2022 | 1.932M |
| September 30, 2022 | 2.123M |
| Date | Value |
|---|---|
| June 30, 2022 | 2.178M |
| March 31, 2022 | 2.762M |
| December 31, 2021 | 1.263M |
| September 30, 2021 | 5.791M |
| June 30, 2021 | 0.7936M |
| March 31, 2021 | 0.5625M |
| December 31, 2020 | 0.6299M |
| September 30, 2020 | 0.6609M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.5625M
Minimum
Mar 2021
5.791M
Maximum
Sep 2021
2.312M
Average
1.932M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| United Therapeutics Corp | 103.50M |
| Tonix Pharmaceuticals Holding Corp | 9.698M |
| Geovax Labs Inc | 4.277M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |